Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

News in Brief

PI3K Inhibitor Improves PFS in BELLE-2 Trial

DOI: 10.1158/2159-8290.CD-NB2015-176 Published February 2016
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Inhibiting the PI3K pathway may be a viable treatment option for women with advanced hormone receptor (HR)–positive breast cancer that becomes resistant to endocrine therapy, according to data presented at the 2015 San Antonio Breast Cancer Symposium in Texas, held December 8–12.

In the phase III BELLE-2 trial, 1,147 patients with advanced or metastatic HR-positive breast cancer that had become resistant to aromatase inhibitor therapy received the estrogen-receptor antagonist fulvestrant (Faslodex; AstraZeneca) for 14 days, after which they received fulvestrant either alone or in combination with the PI3K inhibitor buparlisib (BKM120; Novartis). Researchers also analyzed blood samples in a subset of 587 patients for PIK3CA mutation status.

In the overall study population, progression-free survival (PFS) was 6.9 months in the combination therapy group versus 5.0 months in the control group, meeting the study's primary endpoint. In patients who had PIK3CA mutations detected in their circulating tumor DNA, PFS was longer (7.0 months) if they received the combination therapy versus fulvestrant alone (3.2 months).

“This study suggests that assessment of PIK3CA mutations in circulating tumor DNA may help select patients who benefit from adding a PI3K inhibitor to endocrine therapy,” said senior investigator Mario Campone, MD, PhD, a medical oncologist at the Institute of Oncology West-Rene Gauducheau in Nantes, France, who presented the findings during a press briefing. However, he noted that further studies are needed to confirm whether PIK3CA mutation status can predict response to treatment.

The combination of fulvestrant and buparlisib was associated with serious side effects that caused some patients to discontinue therapy, Campone said. The most common grade 3 and 4 adverse events were liver dysfunction, rash, hyperglycemia, and mood disorders.

Preclinical studies have shown that activation of the PI3K cell-signaling pathway, which can be triggered by PIK3CA mutations, plays a key role in promoting resistance to endocrine therapies, such as aromatase inhibitors. However, many signaling pathways appear to be involved in this type of resistance, possibly explaining why inhibiting PI3K alone produces a statistically significant but modest benefit over standard therapy, said Kent Osborne, MD, director of Baylor College of Medicine's Cancer Center in Houston, TX, and moderator of the press briefing.

Figure1

Using circulating tumor DNA to assess PIK3CA mutations may help oncologists determine which patients might benefit most from endocrine therapy, reported Mario Campone at the San Antonio Breast Cancer Symposium.

“We know that if you block pathways further downstream with [the mTOR inhibitor] everolimus [Afinitor; Novartis], as seen in BOLERO-2, or with [the CDK4/6 inhibitor] palbociclib [Ibrance; Pfizer] in the PALOMA-3 trial, you also get significant benefit,” he said. “We have to identify the many other pathways involved to discover which treatments we can combine for optimal effect.”

In addition, “it will take time before we can tell whether adding a PI3K inhibitor improves overall survival,” said Osborne. “However, this new data gives us more information about the importance of the PI3K pathway in endocrine-resistant disease.” –Janet Colwell

Notes

For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2016 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 6 (2)
February 2016
Volume 6, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
PI3K Inhibitor Improves PFS in BELLE-2 Trial
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
PI3K Inhibitor Improves PFS in BELLE-2 Trial
Cancer Discov February 1 2016 (6) (2) 115-116; DOI: 10.1158/2159-8290.CD-NB2015-176

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PI3K Inhibitor Improves PFS in BELLE-2 Trial
Cancer Discov February 1 2016 (6) (2) 115-116; DOI: 10.1158/2159-8290.CD-NB2015-176
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • By The Numbers: Novel Drugs Approved by the FDA, 2011-2020
  • The National Cancer Act at 50
  • Congress Approves Increase in Cancer Funding
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement